P. Godwin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
P. Godwin has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Marie Baird
Trinity College Dublin
1 shared publication - Kathy Gately
Thoracic Oncology Research Group, Trinity Translational Medicine Institute, Trinity College Dublin, St. James’s Hospital, D08 NHY1 Dublin, Ireland
1 shared publication - Kenneth J. O'Byrne
Department of Clinical Medicine, Thoracic Oncology Research Group, Trinity College Dublin, St. James’s Hospital Ireland Dublin, Ireland
1 shared publication - Martin P. Barr
Thoracic Oncology Research Group, School of Clinical Medicine, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St. James's Hospital & Trinity College Dublin, Dublin, Ireland.
1 shared publication - Susan Heavey
Division of Surgery and Interventional Sciences, University College London, London, UK
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 120
Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy
Intrinsic or acquired resistance to chemotherapeutic agents is a common phenomenon and a major challenge in the treatment of cancer patients. Chemoresistance is defined by a complex network of factors including multi-drug resistance proteins, reduced cellular uptake of the drug, enhanced DNA repair, intracellular drug inactivation, and evasion of apoptosis. Pre-clinical models have demonstrated that many chemotherapy drugs, such as platinum-based agents, antracyclines, and taxanes, promote the activation of the NF-κB pathway. NF-κB is a key transcription factor, playing a role in the development and progression of cancer and chemoresistance through the activation of a multitude of mediators including anti-apoptotic genes. Consequently, NF-κB has emerged as a promising anti-cancer target. Here, we describe the role of NF-κB in cancer and in the development of resistance, particularly cisplatin. Additionally, the potential benefits and disadvantages of targeting NF-κB signaling by pharmacological intervention will be addressed.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 120
Open AccessTargeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy
Intrinsic or acquired resistance to chemotherapeutic agents is a common phenomenon and a major challenge in the treatment of cancer patients. Chemoresistance is defined by a complex network of factors including multi-drug resistance proteins, reduced cellular uptake of the drug, enhanced DNA repair, intracellular drug inactivation, and evasion of apoptosis. Pre-clinical models have demonstrated that many chemotherapy drugs, such as platinum-based agents, antracyclines, and taxanes, promote the activation of the NF-κB pathway. NF-κB is a key transcription factor, playing a role in the development and progression of cancer and chemoresistance through the activation of a multitude of mediators including anti-apoptotic genes. Consequently, NF-κB has emerged as a promising anti-cancer target. Here, we describe the role of NF-κB in cancer and in the development of resistance, particularly cisplatin. Additionally, the potential benefits and disadvantages of targeting NF-κB signaling by pharmacological intervention will be addressed.